2020
DOI: 10.6061/clinics/2020/e2132
|View full text |Cite
|
Sign up to set email alerts
|

COVID-19 and risk management in a tissue bank

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 7 publications
0
3
0
Order By: Relevance
“…Therefore, tissue banks all over the world established strict preventive measures, or in some cases stopped collecting samples. On the other hand, at the moment, no documented reports have proved any COVID-19 infection following tissue transplantation [ 20 , 21 ]. We think that our results could represent a valid basis for further studies related to the possibility of bone donation in patients who suffered and healed from COVID-19.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, tissue banks all over the world established strict preventive measures, or in some cases stopped collecting samples. On the other hand, at the moment, no documented reports have proved any COVID-19 infection following tissue transplantation [ 20 , 21 ]. We think that our results could represent a valid basis for further studies related to the possibility of bone donation in patients who suffered and healed from COVID-19.…”
Section: Discussionmentioning
confidence: 99%
“…Data concerning the risk of SARS-CoV-2 transmission after tissue transplantation are, to date, controversial [ 12 , 13 ]. Recently, several SARS-CoV-2 inactivating procedures have been suggested in the literature for application during human tissue processing, but unfortunately, the most promising of these techniques (i.e., gamma irradiation) is not applicable to valve and PVW processing due to tissue injury [ 14 ]. Thus, in order to implement screening techniques, donor selection parameters, and to better evaluate the theoretical risk of virus transmission within valve transplantation, we tested SARS-CoV-2 presence in PVW samples, preserving pulmonary valve leaflet structures, as well as in other cardiovascular tissues collected at our tissue biobank in the period of April–May 2020 from NPS- and/or BAL-negative tissue donors considered eligible for pulmonary valve (PV) transplant following actual guidelines.…”
Section: Introductionmentioning
confidence: 99%
“…Only emergency or semi emergency cases were done and number of procedures per patient was limited as much as possible. Use of allograft completely stopped as allograft harvesting without proper testing of the donors and protection of the harvesting personnel could increase the risk of transmission of infection (8). Electric dermatome was not used inside the operating theater due to the risk of aerosol generation (9,10).…”
Section: Introductionmentioning
confidence: 99%